This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. GLUE, ATXS, CMPX, MGTX, CSTL, MLTX, RGNX, NAGE, KROS, and ARCTShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Monte Rosa Therapeutics (GLUE), Astria Therapeutics (ATXS), Compass Therapeutics (CMPX), MeiraGTx (MGTX), Castle Biosciences (CSTL), MoonLake Immunotherapeutics (MLTX), REGENXBIO (RGNX), Niagen Bioscience (NAGE), Keros Therapeutics (KROS), and Arcturus Therapeutics (ARCT). These companies are all part of the "med - biomed/gene" industry. Elicio Therapeutics vs. Its Competitors Monte Rosa Therapeutics Astria Therapeutics Compass Therapeutics MeiraGTx Castle Biosciences MoonLake Immunotherapeutics REGENXBIO Niagen Bioscience Keros Therapeutics Arcturus Therapeutics Monte Rosa Therapeutics (NASDAQ:GLUE) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Do analysts prefer GLUE or ELTX? Monte Rosa Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 52.57%. Elicio Therapeutics has a consensus target price of $13.00, indicating a potential upside of 39.04%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Elicio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, GLUE or ELTX? Elicio Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M8.21-$72.70M$0.3627.92Elicio Therapeutics$2.30M66.43-$51.90M-$6.95-1.35 Do institutionals & insiders believe in GLUE or ELTX? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is GLUE or ELTX more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Elicio Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics13.58% 9.95% 6.42% Elicio Therapeutics N/A N/A -175.83% Which has more volatility & risk, GLUE or ELTX? Monte Rosa Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Does the media prefer GLUE or ELTX? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 1 mentions for Monte Rosa Therapeutics and 0 mentions for Elicio Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.36 beat Elicio Therapeutics' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Monte Rosa Therapeutics Neutral Elicio Therapeutics Neutral SummaryMonte Rosa Therapeutics beats Elicio Therapeutics on 12 of the 15 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$152.76M$3.44B$6.21B$10.53BDividend YieldN/A2.28%5.70%4.82%P/E RatioN/A23.1685.7027.13Price / Sales66.43447.86581.22177.04Price / CashN/A46.9237.1060.81Price / Book-9.0810.4112.236.52Net Income-$51.90M-$52.77M$3.33B$276.93M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.1871 of 5 stars$9.35-7.0%$13.00+39.0%+89.7%$152.76M$2.30M0.00N/AAnalyst ForecastGLUEMonte Rosa Therapeutics2.6344 of 5 stars$11.11+4.7%$15.33+38.0%+82.1%$686.14M$177.99M30.8690ATXSAstria Therapeutics1.9225 of 5 stars$11.92+2.7%$25.00+109.7%+4.5%$672.77MN/A-5.9330Trending NewsAnalyst DowngradeHigh Trading VolumeCMPXCompass Therapeutics2.5569 of 5 stars$4.77+9.9%$13.10+174.6%+129.0%$659.61MN/A-10.6020News CoverageMGTXMeiraGTx3.8514 of 5 stars$8.14+2.6%$24.00+194.8%+26.2%$654.86M$33.28M-3.99300CSTLCastle Biosciences3.0932 of 5 stars$22.51+0.7%$36.57+62.5%-32.2%$653.02M$332.07M-64.31540MLTXMoonLake Immunotherapeutics2.8982 of 5 stars$9.89-2.5%$36.00+264.0%-81.4%$635.25MN/A-3.562Trending NewsGap DownHigh Trading VolumeRGNXREGENXBIO4.4402 of 5 stars$12.30+9.3%$28.38+130.7%+5.7%$621.27M$83.33M-3.58370Gap DownNAGENiagen Bioscience2.3108 of 5 stars$7.50+0.4%$13.42+78.9%+109.4%$598.13M$99.60M35.72120KROSKeros Therapeutics3.7148 of 5 stars$14.49-4.0%$30.00+107.0%-77.4%$588.58M$3.55M46.74100News CoverageInsider TradeHigh Trading VolumeARCTArcturus Therapeutics3.5873 of 5 stars$21.57+1.5%$50.57+134.5%-2.3%$585.73M$109.80M-9.67180Positive NewsHigh Trading Volume Related Companies and Tools Related Companies GLUE Competitors ATXS Competitors CMPX Competitors MGTX Competitors CSTL Competitors MLTX Competitors RGNX Competitors NAGE Competitors KROS Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts